Status: current, Defined. Date: 28-Feb 2021. Module: Australian Medicines Terminology module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 4526471000168114 | L.C.E. 50/12.5/200 (carbidopa 12.5 mg + entacapone 200 mg + levodopa 50 mg) tablet, 250 tablets (trade product pack) | en | Fully specified name | Active | Case sensitive | Australian Medicines Terminology module |
| 4526481000168112 | L.C.E. 50/12.5/200 tablet, 250 | en | Synonym | Active | Case sensitive | Australian Medicines Terminology module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| L.C.E. 50/12.5/200 tablet, 250 | Is a | trade product pack | true | Inferred relationship | Some | ||
| L.C.E. 50/12.5/200 tablet, 250 | Is a | levodopa 50 mg + carbidopa 12.5 mg + entacapone 200 mg tablet, 250 | true | Inferred relationship | Some | ||
| L.C.E. 50/12.5/200 tablet, 250 | has TP | L.C.E. 50/12.5/200 | true | Inferred relationship | Some | ||
| L.C.E. 50/12.5/200 tablet, 250 | has TPUU | L.C.E. 50/12.5/200 tablet | true | Inferred relationship | Some | 269020615 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| L.C.E. 50/12.5/200 tablet, 250, bottle | Is a | True | L.C.E. 50/12.5/200 tablet, 250 | Inferred relationship | Some |
Reference Sets
Trade product pack reference set
FHIR